Population Pharmacokinetics of Meropenem in Elderly Patients: Dosing Simulations Based on Renal Function

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2016 Dec 15

PMID 27966034

Citations 20

Authors

Muhammad Usman

Otto R Frey

Georg Hempel

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to evaluate different dosage regimens of meropenem in elderly patients in relation with renal function using a population pharmacokinetic (popPK) model.

Methods: The data of 178 elderly patients treated with meropenem was collected from different sources. A popPK model was developed by using NONMEM® and the influence of different covariates on meropenem CL and V was observed. Monte Carlo dosing simulations were performed at steady state to observe the % T > MIC for targets of 40, 60 and 80% of dosage intervals at different levels of creatinine clearance (CL).

Results: The data was described by a two-compartment model and the values of parameter estimates for CL, V, Q and V were 5.27 L/h, 17.2 L, 9.92 L/h and 10.6 L, respectively. The CL, body weight and centre had a significant influence on meropenem CL while no direct influence of age was observed. Extended infusions had pharmacokinetic and pharmacodynamic (PK/PD) breakpoint one dilution greater than corresponding short infusion regimens for each target of % T > MIC.

Conclusion: Meropenem CL was significantly lower in the elderly compared to CL reported in younger patients due to the reduced renal function. An extended infusion of 1000 mg q8h can be considered for empirical treatment of infections in elderly patients when CL is ≤ 50 mL/min. A continuous infusion of 3000 mg daily dose is preferred if CL > 50 mL/min. However, a higher daily dose of meropenem would be required for resistant strains (MIC >8 mg/L) of bacteria if CL is >100 mL/min.

Citing Articles

Population Pharmacokinetics of Meropenem Across the Adult Lifespan.

Boutzoukas A, Balevic S, Hemmersbach-Miller M, Winokur P, Gu K, Chan A Clin Pharmacokinet. 2024; 64(2):229-241.

PMID: 39681779 DOI: 10.1007/s40262-024-01465-1.

An insight into pharmacokinetics and dose optimization of antimicrobials agents in elderly patients.

Fu G, Sun W, Tan Z, Liang B, Cai Y Front Pharmacol. 2024; 15:1396994.

PMID: 39403139 PMC: 11471682. DOI: 10.3389/fphar.2024.1396994.

Usage of Meropenem Continuous Infusion for Treatment of Infectious Complications in Orthopedic Elderly Patients with Anemia: A Case Series.

Konkayev A, Kadralinova A, Azimova B, Tazhibayeva D, Yeltayeva A, Konkayeva M Medicina (Kaunas). 2024; 60(6).

PMID: 38929546 PMC: 11205918. DOI: 10.3390/medicina60060929.

Pharmacokinetics of Antibacterial Agents in the Elderly: The Body of Evidence.

Butranova O, Ushkalova E, Zyryanov S, Chenkurov M, Baybulatova E Biomedicines. 2023; 11(6).

PMID: 37371728 PMC: 10296334. DOI: 10.3390/biomedicines11061633.

Case report: Successful experience using continuous infusion of meropenem in a geriatric patient with hip fracture complicated by sepsis.

Kadralinova A, Bekniyazova A, Konkayeva M, Yeltayeva A, Konkayev A Front Med (Lausanne). 2023; 10:1148555.

PMID: 37181364 PMC: 10174454. DOI: 10.3389/fmed.2023.1148555.

References

Taccone F, Laterre P, Dugernier T, Spapen H, Delattre I, Wittebole X . Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010; 14(4):R126. PMC: 2945087. DOI: 10.1186/cc9091. View

Zhou Q, He B, Zhang C, Zhai S, Liu Z, Zhang J . Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study. Drugs Aging. 2011; 28(11):903-12. DOI: 10.2165/11595960-000000000-00000. View

Keizer R, van Benten M, Beijnen J, Schellens J, Huitema A . Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2010; 101(1):72-9. DOI: 10.1016/j.cmpb.2010.04.018. View

Shekar K, Fraser J, Taccone F, Welch S, Wallis S, Mullany D . The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Crit Care. 2015; 18(6):565. PMC: 4302127. DOI: 10.1186/s13054-014-0565-2. View

Lindbom L, Pihlgren P, Jonsson E, Jonsson N . PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79(3):241-57. DOI: 10.1016/j.cmpb.2005.04.005. View

Nicolau D . Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008; 47 Suppl 1:S32-40. DOI: 10.1086/590064. View

Isla A, Rodriguez-Gascon A, Troconiz I, Bueno L, Solinis M, Maynar J . Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet. 2008; 47(3):173-80. DOI: 10.2165/00003088-200847030-00003. View

Krueger W, Bulitta J, Kinzig-Schippers M, Landersdorfer C, Holzgrabe U, Naber K . Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother. 2005; 49(5):1881-9. PMC: 1087638. DOI: 10.1128/AAC.49.5.1881-1889.2005. View

Kees M, Minichmayr I, Moritz S, Beck S, Wicha S, Kees F . Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. J Clin Pharmacol. 2015; 56(3):307-15. DOI: 10.1002/jcph.600. View

10.

Udy A, Varghese J, Altukroni M, Briscoe S, McWhinney B, Ungerer J . Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2011; 142(1):30-39. DOI: 10.1378/chest.11-1671. View

11.

Blanchet B, Jullien V, Vinsonneau C, Tod M . Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet. 2008; 47(10):635-54. DOI: 10.2165/00003088-200847100-00002. View

12.

Jaruratanasirikul S, Thengyai S, Wongpoowarak W, Wattanavijitkul T, Tangkitwanitjaroen K, Sukarnjanaset W . Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015; 59(6):2995-3001. PMC: 4432146. DOI: 10.1128/AAC.04166-14. View

13.

Jamal J, Mat-Nor M, Mohamad-Nor F, Udy A, Wallis S, Lipman J . Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents. 2014; 45(1):41-5. DOI: 10.1016/j.ijantimicag.2014.09.009. View

14.

Ikawa K, Morikawa N, Ikeda K, Miki M, Kobayashi M . Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients. J Infect Chemother. 2010; 16(2):139-43. DOI: 10.1007/s10156-009-0025-0. View

15.

Li C, Du X, Kuti J, Nicolau D . Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007; 51(5):1725-30. PMC: 1855547. DOI: 10.1128/AAC.00294-06. View

16.

Spellberg B, Blaser M, Guidos R, Boucher H, Bradley J, Eisenstein B . Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011; 52 Suppl 5:S397-428. PMC: 3738230. DOI: 10.1093/cid/cir153. View

17.

Ulldemolins M, Soy D, Llaurado-Serra M, Vaquer S, Castro P, Rodriguez A . Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother. 2015; 59(9):5520-8. PMC: 4538468. DOI: 10.1128/AAC.00712-15. View

18.

Frippiat F, Musuamba F, Seidel L, Albert A, Denooz R, Charlier C . Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother. 2014; 70(1):207-16. DOI: 10.1093/jac/dku354. View

19.

Craig W . Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26(1):1-10; quiz 11-2. DOI: 10.1086/516284. View

20.

Li C, Kuti J, Nightingale C, Nicolau D . Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006; 46(10):1171-8. DOI: 10.1177/0091270006291035. View